A5101553266- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- RNA modifications and cancer
- Nausea and vomiting management
- Cancer Immunotherapy and Biomarkers
- Anesthesia and Pain Management
- Neuroendocrine Tumor Research Advances
- Head and Neck Cancer Studies
- Multiple and Secondary Primary Cancers
- PI3K/AKT/mTOR signaling in cancer
- Sympathectomy and Hyperhidrosis Treatments
- Cancer-related molecular mechanisms research
- BRCA gene mutations in cancer
- Lymphoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Pancreatic and Hepatic Oncology Research
- Cancer survivorship and care
Sun Yat-sen University
2016-2025
Sun Yat-sen University Cancer Center
2016-2025
Southern Medical University Shenzhen Hospital
2025
Tongji University
2024
State Key Laboratory of Oncology in South China
2016-2024
First Affiliated Hospital of Zhengzhou University
2023
Fudan University
2023
Zhongshan Hospital
2023
Jiangsu Hengrui Medicine (China)
2023
Wenzhou Medical University
2023
Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4-12% of EGFR and are generally refractory to the 1st 2nd generation tyrosine kinase inhibitors (TKIs). Development effective therapies for patients with EGFRex20ins mutant non-small-cell lung carcinoma (NSCLC) represents a great unmet need. Preclinical models have shown that osimertinib is active in NSCLC harboring EGFRex20ins, while antitumor activity remains be evaluated mutations.Tumor...
Abstract Background We aimed to investigate whether more years spent in education are causally associated with a lower risk of lung cancer, through two-sample Mendelian randomization study. Methods The main analysis used publicly available genetic summary data from two large consortia [International Lung Cancer Consortium (ILCCO) and Social Science Genetic Association (SSGAC)]. variants as instrumental variables for were derived SSGAC. Finally, three additional (TAG, GLGC, GIANT) analysed...
Abstract Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct subtype of primary lung cancer characterized by Epstein-Barr virus (EBV) infection. Herein, we reported the mutational landscape pulmonary LELC using whole-exome sequencing, targeted deep sequencing single-nucleotide polymorphism arrays. We identify low degree somatic mutation but widespread existence copy number variations. reveal predominant signature 2 mutations frequent loss type I interferon genes that are...
Patients with small-cell lung cancer (SCLC) patients demonstrate varied survival outcomes. Previous studies have reported that lipoproteins are associated prognosis in various cancers; however, the role of low-density lipoprotein (LDL) and lipoprotein- cholesterol (LDLR) SCLC has not been studied. In this study, impact LDL LDLR on was evaluated. A total 601 were retrospectively evaluated, which 198 had adequate tissues for immunohistochemistry, serum expression levels at baseline tested....
High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations single-region tTMB, multi-region tTMB and bTMB remain to be determined. Moreover, whether intratumor heterogeneity (ITH) has impact on should clarified. We collected tissues matched from 32 operative NSCLC evaluated through a 1021-gene panel sequencing. > 9 mutations/Mb was classified as high....
With the identification of new targetable drivers and recent emergence novel targeted drugs, using comprehensive genomic profiling in lieu routine testing for classic clinical care advanced NSCLC has been increasingly advocated. However, key assumption justifying this practice, that could lead to effective anticancer therapies improve patient outcomes, remains unproved.Comprehensive was prospectively applied 1564 patients identify potentially actionable alterations. Patients were assigned...
Rafeesome, a newly identified multivesicular body (MVB)-like organelle, forms through the fusion of RAB22A-mediated ER-derived noncanonical autophagosomes with RAB22A-positive early endosomes. However, mechanism underlying formation remains unclear. Herein, we report secretory ER-phagy pathway in which assembly RAB22A/TMEM33/RTN4 induces clustering high-molecular-weight RTN4 oligomers, leading to ER membrane remodeling. This remodeling drives biogenesis RTN4-positive autophagosomes, are...
With the improvement of survival for non-small cell lung cancer (NSCLC), research focused on second primary malignancy (SPM) in NSCLC survivors is becoming urgent. This study aimed to estimate risk SPM patients.We retrospectively analysed patients diagnosed between 2004 and 2010 SEER database. We firstly evaluated crude cumulative incidence SPM. compared that reference population was calculated as standardized ratio (SIR). A competing nomogram also built, predict SPM.The 10-year incidences...
The aim of this study is to evaluate the efficacy and safety diacylglycerol (DAG) edible oil intervention in patients with chronic metabolic syndrome complicated by asymptomatic hyperuricemia through a multicenter, prospective, double-blind, randomized controlled clinical trial. A trial involving 176 was designed. All who meet inclusion exclusion criteria will be included either group or B. Group receive DAG-rich (≥ 80%) B conventional cooking (triacylglycerol (TAG)-rich oil) for 12 weeks....
Abstract Background Histone acetyltransferase p300 is a crucial transcriptional coactivator and has been implicated as poor prognostic factor in human cancers. However, little known about the substantial functions mechanisms of NSCLC proliferation distant metastasis. Methods We constructed down-regulated up-regulated cell lines through RNAi recombinant plasmid transfection. Cell Counting Kit-8 assays were used to test confirmed by colony formation assays. Wound healing transwell chamber...
Background: Acquired resistance is a challenge for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. Here, we propose novel treatment strategy based on recent lipid metabolism work. Methods: We applied variety of experimental methods such as immunoblotting, MTT, si-RNA, and animal models, to demonstrate the relationship between EGFR low-density lipoprotein (LDLR) effects statin monotherapy, TKI their combination proliferation at level level. Results: LDLR has...
Abstract Advanced nasopharyngeal carcinoma (NPC) has a poor prognosis, with an unfavorable response to palliative chemotherapy. Unfortunately, there are few effective therapeutic regimens. Therefore, we require novel treatment strategies enhanced efficacy. The present study aimed investigate the antitumor efficacy of APG-1252-M1, dual inhibitor BCL-2/BCL-XL, as single agent and combined gemcitabine. We applied various apoptotic assays used subcutaneous transplanted NPC model assess in vitro...
Lung cancer patients have an increased risk for committing suicide. But no comprehensive study about the suicide issues among non-small-cell lung (NSCLC) has been published. We aimed to estimate trend of rate and identify high-risk group NSCLC patients. Patients diagnosed with primary were identified from Surveillance, Epidemiology, End Results (SEER) database (1973-2013). Suicide mortality (SMR) calculated. Multivariable logistic regression was employed find out independent factors Among...
Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) approved for treatment of advanced non-small cell lung cancer (NSCLC), has been proved to significantly improve progression-free survival (PFS) in first-line setting but suffers from resistance 7–10 months after initiation. Apatinib (YN968D1), a potent vascular endothelial (VEGFR) 2-TKI, specifically binds VEGFR2 and leads anti-angiogenetic anti-neoplastic effect. Concurrent inhibition VEGFR EGFR...
BackgroundPatients with a history of prior cancer are frequently excluded from trials. Previous studies indicated that does not adversely impact clinical outcomes for patients lung older than 65 years. However, it remains unknown whether these results applicable to aged younger years old. The study aimed investigate the on cancer.MethodsWe identified (<65 years) diagnosed between 2004 and 2009 in Surveillance, Epidemiology, End Results database. Propensity score matching was performed...
Many researchers have studied suicide risk factors of patients with one specific cancer. But there is no comprehensive study to compare issues between adolescents and young adult (AYA) group all-age groups in a pan-cancer view.Patients diagnosed 20 solid malignancies were identified from SEER database. Multivariable logistic regression was operated find out suicide.Male sex has less impact on AYA than (OR 2.72, 95% CI: 2.23-3.31, P<0.001 vs. OR 4.64, 4.37-4.94, P<0.001), while white race...